CLOXACILLIN SODIUM FOR INJECTION 2 G
CLOXACILLIN SODIUM : 2 G · DIN 01912410 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is CLOXACILLIN SODIUM FOR INJECTION?
CLOXACILLIN SODIUM FOR INJECTION 2 G contains CLOXACILLIN SODIUM : 2 G. It is listed in the Health Canada Drug Product Database under DIN 01912410, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 01-Dec-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLOXACILLIN SODIUM FOR INJECTION used for?
Treatment of beta-hemolytic streptococcal, pneumococcal, and staphylococcal infections (including beta-lactamase producing strains). Not effective against methicillin-resistant strains.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01912410 |
|---|---|
| Brand name | CLOXACILLIN SODIUM FOR INJECTION |
| Generic / active ingredient | CLOXACILLIN SODIUM : 2 G |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 2 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01CF02 CLOXACILLIN |
| AHFS class | 08:12.16.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Dec-2017 |
| Original market date | 1992-12-31 00:00:00 |
How is it administered?
Adults: 250-500 mg every 6h (max 6g/day). Children <20kg: 25-50 mg/kg/day in 4 doses. Administer by IM or IV injection (2-4 mins) or IV infusion (30-40 mins).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store dry powder at room temperature (up to 25°C). Reconstituted: immediate use recommended; stable 24h at room temp or 48h refrigerated.
How is it supplied?
Vials containing 500 mg, 1000 mg, or 2000 mg of cloxacillin base as the sodium salt.
Contraindications
A history of allergic reactions to penicillin or cephalosporins.
Warnings and precautions
Serious/fatal hypersensitivity (anaphylactoid) reactions. Risk of superinfections (e.g., Candidiasis). CNS effects (seizures) possible in renal failure or inflamed meninges.
Is CLOXACILLIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CF02 CLOXACILLIN. 9 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLOXACILLIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02367416 |
| CLOXACILLIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02400081 |
| CLOXACILLIN FOR INJECTION | 2 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02367424 |
| CLOXACILLIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02367408 |
| JAMP CLOXACILLIN | 250 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02510731 |
| JAMP CLOXACILLIN | 500 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02510758 |
| TEVA-CLOXACILLIN | 125 MG / 5 ML | GRANULES FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 00337757 |
| TEVA-CLOXACILLIN | 250 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00337765 |
| TEVA-CLOXACILLIN | 500 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00337773 |
| APO CLOXI CAP 250MG | 250 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 00618292 |
Who else supplies CLOXACILLIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLOXACILLIN appears in 31 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.